Laurent Audoly, PhD

Kymera Therapeutics
300 Technology Square
Cambridge, MA
USA 02139
Papers:
2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma